Dr Umesh Shaligram, Executive Director & Board Member of Serum Institute of India Pvt. Ltd., spearheads the scientific development of vaccines, especially COVID‐19 vaccines, next generation biologics including biosimilars and biobetters. He oversees unique disease burden reduction and disease elimination using detect, treat and prevent strategies.
He led the development and manufacturing of billions of doses of COVISHIELD® and first indigenously manufactured COVID‐19 vaccine, Covovax/Neuvaxovid (first time in the history of India to supply to US). He guided the team to secure USFDA approval for manufacturing plant at SIIPL.
He is fore‐fronting SIIPL’s strategies for (i) TB eradication with novel products based on detection, prevention and treatment (ii) Malaria elimination, (iii) Pertussis elimination,
(iv) HPV eradication, (v) Point of care CART‐cell therapies and new upcoming therapies.
He has experience of various technologies involved in the field of biologics, biosimilars, biobetters and has led several collaborations, tech‐transfers and business relations with
various companies and research organizations. He is also actively involved in regulatory interaction with several regulatory agencies in the world.